HIV/AIDS

Around the Web — 12.27.22

FDA last week approved lenacapavir (Sunlenca, Gilead), the first of a new capsid inhibitor class, for combination therapy in heavily treatment-experienced adults with multidrug-resistant (MDR)

Read More »